@cdoyle" The ongoing Phase III APPLAUSE-IgAN study is evaluating...

@cdoyle
" The ongoing Phase III APPLAUSE-IgAN study is evaluating the efficacy and safety of twice-daily oral Fabhalta (200 mg) versus placebo in adult IgAN patients on a stable dose of maximally-tolerated renin-angiotensin system (RAS) inhibitor therapy with or without a stable dose of SGLT2i."

"Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001)." [no idea where you get 35% from- the placebo adjusted is reported as 38%, it's not 44-9 because of how the means are calculated statistically I believe, do you understand what placebo-adjusted is??]

https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan

Please learn to read, and stop embarrassing yourself!!!!